BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)

View full entity profile (contributions, contracts, SEC) →

This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.

Lobbying Spend

$4.3M

Filings

Firms Hired

Active Period

2020–2026

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2026	$820,000	3	1
2025	$930,000	4	1
2024	$910,000	5	1
2023	$700,000	4	1
2022	$510,000	4	1
2021	$320,000	4	1
2020	$120,000	3	1

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)	$4,310,000	27

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
HOUSE OF REPRESENTATIVES	25
SENATE	23
Executive Office of the President (EOP)	7
Health & Human Services, Dept of (HHS)	6
Centers For Medicare and Medicaid Services (CMS)	2
Securities & Exchange Commission (SEC)	1

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Health Issues	Health Issues	26
Accounting	Accounting	3
Copyright/Patent/Trademark	Copyright/Patent/Trademark	1
Manufacturing	Manufacturing	1
Financial Institutions/Investments/Securities	Financial Institutions/Investments/Securities	1
Medicare/Medicaid	Medicare/Medicaid	1
Trade (domestic/foreign)	Trade (domestic/foreign)	1

Bills Explicitly Cited (18)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 1119th Congress

An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.

2025 · third_quarter · Firm: BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to drug pricing, including federal proposals impacting reimbursement, access, and affordability; Issues related to Medicare Drug negotiation and implementation of the Inflation Reduction Act; ORPHAN Cures Act and pharmacy benefit manager reform legislation (H.R. 1, One Big Beautiful Bill Act); Issues related to Most Favored Nation (MFN) pricing models

Client expense: $230,000 · Firm income: —

Matched citations: H.R. 1

H.R. 1119th Congress

An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.

2025 · second_quarter · Firm: BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to drug pricing; Issues related to the drug approval and review process; issues related to operations of the Department of Veterans Affairs including work with clinical trials and research studies; implementation of the Inflation Reduction Act; ORPHAN Cures Act and pharmacy benefit manager legislation; ORPHAN Cures Act language in H.R. 1, One Big Beautiful Bill Act

Client expense: $220,000 · Firm income: —

Matched citations: H.R. 1

H.R. 5539118th Congress

ORPHAN Cures Act

2024 · second_quarter · Firm: BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to drug pricing, implementation of the Inflation Reduction Act, and the ORPHAN Cures Act (H.R. 5539); pharmacy benefit managers legislation; the Food & Drug Administration; issues related to FDA Regulatory Framework and Interaction; informational inquiry related to the BIOSECURE Act (H.R. 8333)

Client expense: $160,000 · Firm income: —

Matched citations: H.R. 5539

H.R. 8333118th Congress

BIOSECURE Act

2024 · second_quarter · Firm: BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to drug pricing, implementation of the Inflation Reduction Act, and the ORPHAN Cures Act (H.R. 5539); pharmacy benefit managers legislation; the Food & Drug Administration; issues related to FDA Regulatory Framework and Interaction; informational inquiry related to the BIOSECURE Act (H.R. 8333)

Client expense: $160,000 · Firm income: —

Matched citations: H.R. 8333

Show 14 more cited filings

H.R. 5539118th Congress

ORPHAN Cures Act

2024 · first_quarter · Firm: BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to drug pricing, implementation of the Inflation Reduction Act, and the ORPHAN Cures Act (H.R. 5539); pharmacy benefit managers legislation; 340B drug discount program; the Food & Drug Administration; issues related to FDA Regulatory Framework and Interaction; informational inquiry related to the BIOSECURE Act (H.R. 7085)

Client expense: $240,000 · Firm income: —

Matched citations: H.R. 5539

H.R. 7085118th Congress

BIOSECURE Act

2024 · first_quarter · Firm: BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to drug pricing, implementation of the Inflation Reduction Act, and the ORPHAN Cures Act (H.R. 5539); pharmacy benefit managers legislation; 340B drug discount program; the Food & Drug Administration; issues related to FDA Regulatory Framework and Interaction; informational inquiry related to the BIOSECURE Act (H.R. 7085)

Client expense: $240,000 · Firm income: —

Matched citations: H.R. 7085

H.R. 5539118th Congress

ORPHAN Cures Act

2023 · fourth_quarter · Firm: BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to drug pricing, implementation of the Inflation Reduction Act, and the ORPHAN Cures Act (H.R. 5539); pharmacy benefit managers legislation; 340B drug discount program; the Food & Drug Administration; issues related to FDA Regulatory Framework and Interaction

Client expense: $140,000 · Firm income: —

Matched citations: H.R. 5539

H.R. 3117th Congress

Elijah E. Cummings Lower Drug Costs Now Act

2022 · third_quarter · Firm: BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)

Open original LDA filing ↗

Cited source text and reported amounts

Discussions on registrant's background, products, and pipeline generally; FDA Reform/Prescription Drug User Fee Act (PDUFA) reauthorization; Issues related to prescription drug pricing reform/policies; H.R.3 - Elijah E. Cummings Lower Drug Costs Now Act; Draft 21st Century Cures Act 2.0 legislation; DIVERSE Trials Act

Client expense: $140,000 · Firm income: —

Matched citations: H.R.3

H.R. 3117th Congress

Elijah E. Cummings Lower Drug Costs Now Act

2022 · second_quarter · Firm: BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)

Open original LDA filing ↗

Cited source text and reported amounts

Discussions on registrant's background, products, and pipeline generally; FDA Reform/Prescription Drug User Fee Act (PDUFA) reauthorization; Issues related to prescription drug pricing reform/policies; H.R.3 - Elijah E. Cummings Lower Drug Costs Now Act; Draft 21st Century Cures Act 2.0 legislation; DIVERSE Trials Act

Client expense: $160,000 · Firm income: —

Matched citations: H.R.3

H.R. 3117th Congress

Elijah E. Cummings Lower Drug Costs Now Act

2022 · first_quarter · Firm: BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)

Open original LDA filing ↗

Cited source text and reported amounts

Discussions on registrant's background, products, and pipeline generally; FDA Reform/Prescription Drug User Fee Act (PDUFA) reauthorization; Issues related to prescription drug pricing reform/policies; H.R.3 - Elijah E. Cummings Lower Drug Costs Now Act; Draft 21st Century Cures Act 2.0 legislation; DIVERSE Trials Act

Client expense: $90,000 · Firm income: —

Matched citations: H.R.3

H.R. 3117th Congress

Elijah E. Cummings Lower Drug Costs Now Act

2021 · fourth_quarter · Firm: BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)

Open original LDA filing ↗

Cited source text and reported amounts

Discussions on registrant's background, products, and pipeline generally; FDA Reform/Prescription Drug User Fee Act (PDUFA) reauthorization; Issues related to prescription drug pricing reform/policies; H.R.3 - Elijah E. Cummings Lower Drug Costs Now Act; Draft 21st Century Cures Act 2.0 legislation

Client expense: $80,000 · Firm income: —

Matched citations: H.R.3

H.R. 3117th Congress

Elijah E. Cummings Lower Drug Costs Now Act

2021 · third_quarter · Firm: BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)

Open original LDA filing ↗

Cited source text and reported amounts

Discussions on registrant's background, products, and pipeline generally; FDA Reform/Prescription Drug User Fee Act (PDUFA) reauthorization; Issues related to prescription drug pricing reform/policies; H.R.3 - Elijah E. Cummings Lower Drug Costs Now Act; Draft 21st Century Cures Act 2.0 legislation

Client expense: $80,000 · Firm income: —

Matched citations: H.R.3

H.R. 3117th Congress

Elijah E. Cummings Lower Drug Costs Now Act

2021 · second_quarter · Firm: BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)

Open original LDA filing ↗

Cited source text and reported amounts

Discussions on registrant's background, products, and pipeline generally; FDA Reform/Prescription Drug User Fee Act (PDUFA) reauthorization; Issues related to prescription drug pricing reform/policies; H.R.3 - Elijah E. Cummings Lower Drug Costs Now Act; Draft 21st Century Cures Act 2.0 legislation

Client expense: $80,000 · Firm income: —

Matched citations: H.R.3

H.R. 7000116th Congress

Holding Foreign Companies Accountable Act

2020 · fourth_quarter · Firm: BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)

Open original LDA filing ↗

Cited source text and reported amounts